Cite
HARVARD Citation
Dummer, R. et al. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet oncology. 21 (3), pp. 358-372. [Online].